Standard dosing for semaglutide and tirzepatide is designed to balance efficacy against tolerability. Most patients can follow standard titration; some need to slow it down. This guide covers the schedules, the rationale, and legitimate reasons to deviate.
Semaglutide for weight (Wegovy)
| Week | Dose | Notes |
|---|---|---|
| 1–4 | 0.25 mg/week | Initiation; minimal weight effect expected |
| 5–8 | 0.5 mg/week | Modest weight effect begins |
| 9–12 | 1.0 mg/week | Most patients see meaningful appetite reduction |
| 13–16 | 1.7 mg/week | Approaching maintenance |
| 17+ | 2.4 mg/week | Maintenance; continued indefinitely if tolerated |
Tirzepatide for weight (Zepbound)
| Week | Dose | Notes |
|---|---|---|
| 1–4 | 2.5 mg/week | Initiation |
| 5–8 | 5 mg/week | First effective dose |
| 9–12 | 7.5 mg/week | Continue if escalation tolerated |
| 13–16 | 10 mg/week | Common maintenance level |
| 17–20 | 12.5 mg/week | Continued escalation if needed |
| 21+ | 15 mg/week | Maximum; not all patients need to reach this |
Rationale for slow titration
Dose-limiting side effects (nausea, GI symptoms) are mechanism-related. Slow titration allows tolerance to develop. Skipping steps significantly increases discontinuation risk.
When to deviate
- Slow the schedule if a dose step produces intolerable symptoms — hold for 4 more weeks, then re-attempt.
- Hold at sub-maximum dose if weight goals are being met. Going higher just because the protocol allows is not required.
- Re-escalate after a break at the dose you were at, not the next step. Tolerance may not persist through long breaks.
What "maintenance dose" means in practice
Many patients stabilize at sub-maximum dose that produces target effect with acceptable side effects. The question is not "did you reach max" but "is current dose working for your goals."
Missed doses
- If <48 hours ago: take as soon as possible, resume normal schedule.
- If >48 hours: skip the missed dose, take the next regularly scheduled dose.
- If multiple consecutive doses missed: consult prescriber; may need to re-titrate.
The flat-rate pricing connection
Programs with dose-step pricing create a financial incentive to stay at lower doses than clinically optimal. Flat-rate programs (NexLife) remove this incentive — titration is a clinical decision, not a budget decision.